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OBJECTIVES: To determine whether antidepressants as a group,
as well as each individual drug, increases the incidence of major
malformations above the baseline of 1–3%. METHODS: At The
Motherisk Program, we analyzed pregnancy outcomes of 1243
women from prospectively collected cases in our database, who
were exposed to antidepressants during pregnancy. We then com-
pared them to a matched comparison group of 1243 women who
were not exposed (non-teratogen group) and the two groups
were compared for the incidence of major malformations.
RESULTS: A total of 928 women who ﬁt the criteria for inclu-
sion, who were exposed in the 1st trimester of pregnancy, were
matched to 928 women in the comparison group. Antidepres-
sants in the analysis included: bupropion (113) citalopram (184),
escitalopram (21), ﬂuvoxamine (52), ﬂuoxetine (61), mirtazepine
(68), nefazodone (49), paroxetine (148), sertraline (61) traz-
odone (17), venlafaxine (154). There were 24 (2.5%) major
malformations in the antidepressant group and 25 (2.6%) in the
comparison group: (RR = 0.96, CI95%:0.55–1.67). CONCLU-
SIONS: First trimester exposure to antidepressants as a group
was not associated with an increased incidence of major malfor-
mations above baseline. In addition, no individual antidepressant
was associated with an increased risk of a speciﬁc malformation.
The results of this study will add to the current literature in this
ﬁeld, as there has been conﬂicting data. Pregnant women requir-
ing antidepressants in pregnancy and their health care providers,
will ﬁnd this information reassuring.
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OBJECTIVES: To examine the methodological quality of eco-
nomic evaluation studies in obstetrics, gynaecology and repro-
ductive medicine published from 1997 to 2008 and compare it
with studies published between 1990 and 1997. METHODS: A
checklist was constructed by using several existing checklists for
methodological quality of economic evaluations and consisted of
30 quality criteria. Each of the articles was reviewed indepen-
dently by two reviewers. Literature searches were performed in
23 obstetrics, gynaecology and/or reproductive medicine journals
in Medline for the years 1997 through 2007. The following
search strategy was used: “Cost-Beneﬁt analysis”(Mesh) OR
“Cost-beneﬁt” OR “Cost-effectiveness”, and “Costs and Cost
Analysis”[Mesh]. This search resulted in 615 articles concerning
an economic analysis. Letters, comments, reviews and no full
economic evaluations were excluded. The quality of studies was
compared to a similar study that reported on the period 1990
through 1997. RESULTS: In our review 155 articles from 12
journals were included. The majority of the studies (57%) con-
cerned obstetrics, whereas 37% dealt with gynaecology and 7%
dealt with reproductive medicine. Most articles reported cost-
effectiveness (55%), whereas 8% concerned cost-utility analyses.
The mean number of criteria adhered to was 16.7 out of the
30 items. Highest score was met for the criteria ‘description of
competing alternatives’ (95%). Only 16% of all the studies
reported the perspective of the analysis, which is comparable
to a previous review (19%). The primary outcomes are clearly
stated in 92% of the studies, and that is better than in the earlier
review (72%). More incremental (57% vs. 17%) and sensitivity
analyses (66% vs. 21%) were reported as well. CONCLU-
SIONS: The methodological quality of economic evaluation
studies published during the last decade in obstetrics, gynaecol-
ogy and/ or reproductive medicine journals considerably im-
proved since an earlier review reported over the years before.
However, improvement is still needed on several topics.
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OBJECTIVES: To study the economic impact of a delay of treat-
ment with 6 monts in couples with unexplained subfertility.
METHODS: The economic analysis was performed from the
perspective of the health care institution. Subfertile couples with
unexplained subfertility and a moderate prognosis for treatment-
independent pregnancy were randomly assigned to intra uterine
insemination with controlled ovarian hyperstimulation (IUI
COH) (early treatment group) or 6 months expected manage-
ment (expectant management group). After the initial study of 6
months, couples were managed according to local protocol. We
registered the number of treatment cycles with IUI and IVF, as
well as the ongoing pregnancy rates in both groups. RESULTS:
In the early treatment group, 94 couples started with IUI-COH
and underwent 505 treatment cycles (5.4 cycle per couple). In the
expectant management group, 67 couples started with IUI-COH
and underwent 311 treatment cycles (5.4 cycle per couple). For
IVF, In the early treatment group, 40 couples started with IVF
and underwent 79 treatment cycles (2.0 cycle per couple). In the
expectant management group, 27 couples started with IVF and
underwent 53 treatment cycles (2.0 cycle per couple). Early treat-
ment with IUI signiﬁcantly increased the risk of a couples starting
with IVF (RR 1.6, 95% CI 1.0 to 2.3). The average costs per
couple were €3821 after early treatment versus €2322 after
expectant management (P-value < 0.001). When this saving in
health care costs would be made available to the couples without
an ongoing pregnancy after three years, these couples could
undergo an additional three cycles of IVF per couple. CONCLU-
SIONS: Couples with unexplained subfertility and an inter-
mediate prognosis for treatment independent pregnancy, delay
of treatment for 6 months will result in reduction of health care
costs of 1500 euros per couple without compromising the
ongoing pregnancy rates.
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